Document Detail

Clinical experience with the combined use of recombinant interleukin-2 (IL2) and interferon alfa-2a (IFN alpha) in metastatic melanoma.
MedLine Citation:
PMID:  1931717     Owner:  NLM     Status:  MEDLINE    
A multicentre study of IL2 and IFN alpha has been performed in 58 patients with metastatic melanoma. The scheme consisted of IL2 3.0 BRMP MU/m2/d as a continuous infusion for 4 d combined with subcutaneous administration of IFN alpha 6 MU/m2/d, day 1 + 4. The cycle was repeated every 2 weeks for a maximum duration of 26 weeks. 54 patients were evaluable for response. One (2%) achieved a complete and 10 (19%) a partial response. 19 (35%) patients were stable and 24 (44%) showed progressive disease. Common side-effects included fever, chills, fatigue, skin rash, anorexia, nausea and diarrhoea. Hypothyroidism was noted in 10% of the patients. These results show that this regimen of IL2 and IFN alpha is active but, in contrast to what could be expected, not superior to IL2 alone possibly due to suboptimal dosing. In an ongoing study in Rotterdam and Nijmegen, a more intense schedule was chosen, consisting of three daily i.v. doses of IL2 4.5 BRMP MU/m2 and IFN alpha 3.0 MU/m2 for 5 d. This regimen is repeated at intervals of 3 weeks for a total of three cycles. Presently, nine patients have been entered. One patient achieved a complete response, four a partial response (overall 56%), three had stable disease and one progressed. Toxicity was severe and treatment was prematurely stopped in five patients: myocardial infarction (one patient), atrial fibrillation (one patient), negative T waves and myocardial hypokinesia (one patient) and psychosis (two patients). This regimen can only be justified if the therapeutic results are superb, which has yet to be awaited.
W H Kruit; S H Goey; J R Monson; R A Stahel; F Calabresi; R Mertelsmann; E E Holdener; A M Eggermont; R L Bolhuis; P H de Mulder
Related Documents :
9919447 - Predictors of success in the conversion of new-onset atrial fibrillation using oral pro...
11225937 - Stroke prevention practices in patients with atrial fibrillation and pacemaker therapy:...
8911237 - Status of antithrombotic therapy for patients with atrial fibrillation in university ho...
11170327 - Transcatheter closure of atrial septal defects and patent foramen ovale under intracard...
18280287 - Transhepatic central venous catheter for long-term access in paediatric patients.
6309987 - Polymorphonuclear leukocyte function in psoriasis: chemotaxis, chemokinesis, beta-adren...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  British journal of haematology     Volume:  79 Suppl 1     ISSN:  0007-1048     ISO Abbreviation:  Br. J. Haematol.     Publication Date:  1991 Oct 
Date Detail:
Created Date:  1991-12-19     Completed Date:  1991-12-19     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  0372544     Medline TA:  Br J Haematol     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  84-6     Citation Subset:  IM    
Rotterdam Cancer Institute, The Netherlands.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Drug Administration Schedule
Drug Evaluation
Interferon Alfa-2a / administration & dosage,  adverse effects,  therapeutic use*
Interleukin-2 / administration & dosage,  adverse effects,  therapeutic use*
Melanoma / secondary*,  therapy
Middle Aged
Recombinant Proteins / therapeutic use
Reg. No./Substance:
0/Interleukin-2; 0/Recombinant Proteins; 76543-88-9/Interferon Alfa-2a

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Interferon in combination with antitumourigenic phenyl derivatives: potentiation of IFN alpha activi...
Next Document:  Signal transduction pathway activating interferon-alpha-stimulated gene expression.